Biodistribution, Pharmacokinetics, and Safety of F-18 THK-5351 PET in Alzheimer's Disease Patients and Healthy Subjects

Trial Profile

Biodistribution, Pharmacokinetics, and Safety of F-18 THK-5351 PET in Alzheimer's Disease Patients and Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Feb 2017

At a glance

  • Drugs Fluorine 18 THK 5351 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 06 Feb 2017 Status changed from recruiting to completed.
    • 23 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top